RankingsPricing
  1. US-listed companies
  2. CATALYST PHARMACEUTICALS, INC.
  3. Raw

CATALYST PHARMACEUTICALS, INC.CPRX

Market cap
$2.9B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net income--------34,003,5143275398371164
Depreciation---26,57434,46843,40645,68937,97854,32792,0650000
Stock-based compensation666777,969222446681422
Amortization of intangible assets-----------13337
Deferred taxes---------33-9-5189
Accretion of discount-------------11
Non cash change in right of use asset--------243,399793,2520000
Debt Securities, Available-for-Sale, Realized Loss-----------1--
Acquired inventory samples expensed from asset acquisition------------0-
Acquired in-process research and development------------82-
Change in fair value of equity securities------------35
Accounts receivable, net--------11-4,549,571144312
Inventory-------56,012233-154
Prepaid expenses and other current assets208,004123452,040-456,794125,800476,03734-4169
Accounts payable263,9341850,789963,421-20,083-860,9511391,7922138,573-11112
Accrued expenses and other liabilities516,033239,528131-480,2481513-1,209,280616654
Operating lease liability--------276,807919,2801-0-0-0
Net cash provided by (used in) operating activities-4,985,049-5,140,366-9,875,674-----25,704,406354560116144240
Purchases of property and equipment102,826155,208164,64057,32323,46596,061-92,01819,36911,3981001
Proceeds from sale of available-for-sale securities-----------19--
Payments in connection with asset acquisitions------------198-
Acquisition of in-process research and development------------82-
Purchase of equity securities------------13-
Net cash provided by (used in) investing activities-3,620-14,059,651-7,496,801-----15,526,01137-5,011,398-119-294-1
Payment of employee withholding tax related to stock-based compensation3,4103,4103,410--11,265-4,448-56,1970011
Proceeds from Stock Options Exercised--23,500522,000390,35180,251368,185297,5631758,130410314
Repurchase of common stock----------127--
Payment of liabilities arising from asset acquisition-----------11313
Proceeds from issuance of common stock-43-----------141
Payment of fees in connection with issuance of common stock-------------0
Net cash provided by (used in) financing activities375270----293,1151701,933-82-11141
Net increase (decrease) in cash and cash equivalents--------734141127-161380
Income Taxes Paid---------3385068
Cash paid for interest------------11
Operating lease liabilities arising from obtaining right-of-use assets----------3---
Liabilities arising from asset acquisition-----------282-